The FDA granted orphan drug designation to CTD402 for relapsed or refractory T-cell acute lymphoblastic leukemia and ...
The change is expected to save at least 90 days in the drug development life cycle — a major boost for research timelines and ...
The global rise of antimicrobial resistance (AMR) among pathogenic microorganisms is widely recognised as one of the most pressing challenges in ...
Real-World Data and Real-World Evidence (RWD/RWE) have been utilized not only for drug safety assessment but also for ...
Drug companies have announced a slew of deals for tools to unleash the promise of AI, seen as the biggest technological ...
Libevitug works by blocking hepatitis B and D viruses from entering liver cells, targeting the PreS1 domain of the viral ...
Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.
Optimized frameworks for efficient and scalable deployment of digital health technologies (DHT) are needed to address existing bottlenecks and unlock the opportunities for remote monitoring and ...
The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...
To this day, animal testing remains one of the most controversial issues in animal rights. Activists have been fighting ...
The FDA granted orphan drug designation to zavabresib, an investigational therapy for the treatment of myelofibrosis, a rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results